  |
|
03.09.2010 OvPlex™
launched in Asia |
|
HealthLinx
Limited
Singapore
distribution partner INEX Innovation Exchange
Pte Ltd has launched OvPlex™ in Singapore
yesterday. Under the terms of its
agreement with HealthLinx, INEX will have the
exclusive rights to market, sell and distribute
OvPlex™
for a period
of ten years. Singapore will serve as the
platform to launch into the region including
India, Malaysia, Thailand, Indonesia and
Vietnam.
 |
 |
|
|
|
  |
|
|
02.09.2010 Anti-Cancer Agent, Xeloda®
Filed for Advanced or Refractory Gastric Cancer By “New Drug
Application Based on Evidence in the Public Domain” |
|
Chugai Pharmaceutical
Co., Ltd. [Head Office: Chuo-ku, Tokyo;
President: Osamu Nagayama (hereafter, "Chugai")]
announced today that
it filed on September 1, a “new drug application
(NDA) based on evidence in the public domain”
with the Japanese Ministry of Health, Labour and
Welfare (MHLW), seeking approval for the
indication “advanced or refractory gastric
cancer in patients who are not candidates for
curative surgery” for the anti-cancer agent
capecitabine (brand name: Xeloda®
Tablet 300, hereafter, “Xeloda®”). In
Japan, Xeloda® is currently marketed
for the indications of “inoperable or recurrent
breast cancer,” “postoperative adjuvant
chemotherapy for colon cancer,” and “advanced or
refractory colorectal cancer in patients who are
not candidates for curative surgery.”
|
|
|
|
|
  |
|
|
02.09.2010 MorphoSys Initiates
Program Against Drug-Resistant MRSA Infections |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) announced
today a new proprietary development program against novel infectious
disease targets. As part of this initiative, MorphoSys has signed a
license and collaboration agreement with UK-based Absynth Biologics,
providing access to novel target molecules associated with
Staphylococcus aureus
infections including MRSA (methicillin-resistant
S. aureus).
MorphoSys will generate antibodies using its proprietary HuCAL
PLATINUM antibody library which Absynth will test in relevant
disease models. MorphoSys will be solely responsible for the
development and partnering of the resulting compounds. Absynth will
receive an upfront payment and is eligible for development-dependent
milestone payments and royalties. Further financial details were not
disclosed.
|
 |
|
|
|
|
|
|
|
|
|
|
All rights reserved